Bessemer Group
HRTX icon

Bessemer Group’s Heron Therapeutics HRTX Stock Holding History

Bessemer Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,300
Closed -$2K – 2589
2025
Q4 		$2K Hold
1,300
– – ﹤0.01% 2418
2025
Q3 		$2K Hold
1,300
– – ﹤0.01% 2322
2025
Q2 		$3K Hold
1,300
– – ﹤0.01% 2132
2025
Q1 		$3K Sell
1,300
-125
-9% -$243 ﹤0.01% 2147
2024
Q4 		$2K Hold
1,425
– – ﹤0.01% 2218
2024
Q3 		$3K Buy
+1,425
New +$3.4K ﹤0.01% 2098

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Bessemer Group's HRTX Position: Q1 2026 in Review

Bessemer Group sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 1,300 shares — an estimated $2K sold.

Bessemer Group first reported a position in HRTX in Q3 2024 and held it in 6 quarters. The position peaked at $3K in Q2 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Bessemer Group reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bessemer Group sold 1,300 Heron Therapeutics shares in Q1 2026, an estimated $2K.
  • Bessemer Group first reported a position in Heron Therapeutics in Q3 2024 and held it in 6 quarters.
  • Bessemer Group's Heron Therapeutics position peaked at $3K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.